The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
roche completes 1.5 billion acquisition of poseida therapeutics
Roche Holdings has finalized its tender offer to acquire Poseida Therapeutics for approximately $1.5 billion, agreeing to pay $9.00 per share for nearly 65 million shares, representing 66% of Poseida’s outstanding stock. The deal includes a potential additional payment of up to $4.00 per share. Following the acquisition, Poseida will become a wholly owned subsidiary of Roche, and its shares will be delisted from the Nasdaq Global Select Market.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.